Picture loading failed.

Anti-CSF1R therapeutic antibody (Pre-made Emactuzumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Emactuzumab (RG-7155) is a humanized monoclonal antibody directed against CSF-1R expressed on macrophages[ and has demonstrated a profound antitumor effect through interference with the CSF-1/CSF-1R axis, along with a manageable safety profile in patients with diffuse-type tenosynovial giant cell tumors (d-TGCT)

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-174-1mg 1mg 3090
GMP-Bios-ab-174-10mg 10mg 21890
GMP-Bios-ab-174-100mg 100mg 148000
GMP-Bios-ab-174-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-CSF1R therapeutic antibody (Pre-made Emactuzumab biosimilar,Whole mAb)
INN Name Emactuzumab
TargetCSF1R
FormatWhole mAb
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusActive
100% SI Structure4liq:HL
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2014
Year Recommended2015
CompaniesRoche;University of Texas M. D. Anderson Cancer Center
Conditions Approvedna
Conditions ActiveFallopian tube cancer;Ovarian cancer;Peritoneal cancer;Solid tumours
Conditions DiscontinuedGiant cell tumour of tendon sheath;Pigmented villonodular synovitis
Development Techna